We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.6B
AUM Growth
+$886M
Cap. Flow
+$142M
Cap. Flow %
2.54%
Top 10 Hldgs %
40.08%
Holding
154
New
29
Increased
38
Reduced
31
Closed
27

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.3M
2
BMY icon
Bristol-Myers Squibb
BMY
+$82.6M
3
SHPG
Shire pic
SHPG
+$76.4M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.3M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$49.2M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$149M
2
INCY icon
Incyte
INCY
+$33.4M
3
MAKO
MAKO SURGICAL CORP COM
MAKO
+$26.7M
4
PFE icon
Pfizer
PFE
+$25.6M
5
AGN
Allergan plc
AGN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Financials 1.77%
3 Technology 0.15%
4 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQL
76
DELISTED
Arqule Inc
ARQL
$10.2M 0.18%
4,366,000
+1,562,000
+56% +$3.92M
CAH icon
77
Cardinal Health
CAH
$54.6B
$9.87M 0.18%
189,300
– –
VPHM
78
CALL
DELISTED
VIROPHARMA INC
VPHM
$9.81M 0.18%
+250,000
New +$8.17M
MCK icon
79
McKesson
MCK
$106B
$9.75M 0.17%
76,000
– –
PTLA
80
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.75M 0.16%
327,000
-153,319
-32% -$3.65M
CRIS icon
81
Curis
CRIS
$9.82M
$8.7M 0.16%
975
– –
ACAD icon
82
Acadia Pharmaceuticals
ACAD
$4.45B
$8.57M 0.15%
312,000
-981,000
-76% -$20.5M
VCRA
83
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$8.32M 0.15%
447,500
– –
GEVA
84
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$8.24M 0.15%
+130,000
New +$6.4M
PRGO icon
85
CALL
Perrigo
PRGO
$1.45B
$8.19M 0.15%
+66,400
New +$8.29M
HNT
86
CALL
DELISTED
HEALTH NET INC
HNT
$7.92M 0.14%
+250,000
New +$7.89M
NSPR icon
87
InspireMD
NSPR
$32.3M
$7.91M 0.14%
1
– –
AVNR
88
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$7.88M 0.14%
+1,863,400
New +$8.83M
MOH icon
89
CALL
Molina Healthcare
MOH
$10.6B
$7.67M 0.14%
+215,300
New +$7.95M
DVA icon
90
DaVita
DVA
$15.5B
$7.4M 0.13%
130,000
– –
JAZZ icon
91
Jazz Pharmaceuticals
JAZZ
$16.1B
$6.62M 0.12%
72,000
– –
NBIX icon
92
Neurocrine Biosciences
NBIX
$18.2B
$6.51M 0.12%
575,000
-193,000
-25% -$2.65M
STJ
93
DELISTED
St Jude Medical
STJ
$6.44M 0.11%
120,000
-25,000
-17% -$1.29M
PTX
94
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$6.31M 0.11%
232,080
– –
BLUE
95
DELISTED
bluebird bio
BLUE
$6M 0.11%
+17,177
New +$6.38M
CPRX
96
DELISTED
Catalyst Pharmaceutical
CPRX
$5.78M 0.1%
+1,895,000
New +$3.19M
FRX
97
DELISTED
FOREST LABORATORIES INC
FRX
$5.13M 0.09%
120,000
– –
UPI
98
DELISTED
UROPLASTY INC-NEW
UPI
$4.78M 0.09%
1,443,500
– –
ENDP
99
DELISTED
Endo International plc
ENDP
$4.77M 0.09%
+105,000
New +$4.22M
SUPN icon
100
Supernus Pharmaceuticals
SUPN
$2.75B
$4.69M 0.08%
639,400
-1,856,800
-74% -$12.5M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2013 Portfolio in Review

As of Q3 2013, OrbiMed held 154 positions worth $5.6B, up 19% from $4.72B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2013 filing shows 29 new, 38 increased, 31 reduced and 27 closed positions. Its largest new stake was Shire pic: 690,900 shares worth $82.8M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2013 buy was Shire pic: 690,900 shares worth $82.8M.
  • OrbiMed added most to Merck in Q3 2013, an estimated $93.3M increase.
  • OrbiMed's biggest Q3 2013 reduction was Incyte, cutting an estimated $33.4M.
  • OrbiMed fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 40% of its $5.6B portfolio in Q3 2013.
  • OrbiMed opened 29 new positions and closed 27 in Q3 2013.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $5.6B.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.